Clinical Trial Update: ACY-1215 for Relapsed/Refractory Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ACY-1215 (ricolinostat) in relapsed/refractory lymphoid malignancies reports Phase 1/2 results; the study has been terminated with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Neoplasms
• Lymphoma

Drugs mentioned

• ACY-1215 (ricolinostat)

Snippet

Sponsor: Jennifer Amengual | Conditions: Lymphoma, Lymphoid Malignancies | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-06